Corporate | 15 July 2010 10:49
WILEX AG / Offer
15.07.2010 10:49
Dissemination of a Corporate News, transmitted by
DGAP - a company of EquityStory AG.
The issuer / publisher is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
WILEX AG receives tender offer for a mandatory take over bid by dievini
Hopp BioTech holding
Munich, 15 July 2010. WILEX AG (ISIN DE0006614720 / WL6 / Frankfurt Stock
Exchange) received a tender offer for a mandatory takeover bid by dievini
Hopp BioTech Holding GmbH & Co. KG, Walldorf, Germany (dievini) late
yesterday evening. The German Federal Financial Supervisory Authority
(BaFin) has reviewed and approved the offer document.
dievini is obliged under section 35 para. 2 German Securities Acquisition
and Takeover Act (WpÜG) to make an offer to acquire all of WILEX's bearer
shares after exceeding the control threshold of 30% of the Company's voting
rights on 2 June 2010. dievini now has an equity interest of 35.65% in
WILEX.
The offer price is EUR 4.10 per share and exceeds the statutory minimum
price of EUR 4.07. The acceptance period for the offer starts to run on 15
July 2010 and ends at midnight CET on 12 August 2010. The Executive
Management Board and the Supervisory Board of WILEX AG will issue a
statement regarding the mandatory offer.
The offer document will be posted solely in German on the web pages of both
the prospective buyer (www.dievini.com) and WILEX AG (www.wilex.de) from 15
July 2010 onwards and made available for inspection, at no charge, by DZ
BANK AG Deutsche Zentral-Genossenschaftsbank, Frankfurt/Main, Abteilung
F/GTKS, Platz der Republik, 60265 Frankfurt/Main, Germany, Fax: + 49 (0) 69
7447 3685 ('DZ BANK').
About WILEX AG
WILEX AG is a biopharmaceutical company based in Munich and is listed at
the Frankfurt Stock Exchange at the Regulated Market / Prime Standard.
WILEX's mission is to develop drugs with a low side effect profile and
targeted treatment of different types of cancer as well as diagnostic
agents for specific detection of tumours. The Company's product candidates
are based on antibodies and small molecules. WILEX has an attractive
product pipeline which includes both drug and diagnostic candidates: A
pivotal Phase III study with REDECTANE(R) has been completed and positive
data published. RENCAREX(R) is undergoing a Phase III registration trial.
Positive MESUPRON(R) Phase II data in the indication pancreatic cancer have
been published and another Phase II trial in breast cancer is ongoing. The
MEK inhibitor WX-554 has completed a Phase I trial. A further oncology
project (PI3K inhibitor WX-037) is in preclinical development and three
antibody programmes are in research. WILEX aims within a few years to be
able to finance its research and development programmes from its operating
cash flow. Website: http://www.WILEX.com, ISIN DE0006614720 / WKN 661472 /
Symbol WL6
Contact
WILEX AG
Corporate Communications
Katja Arnold (CIRO)
Grillparzerstr. 10
81675 Munich, Germany
Tel.: +49 (0)89-41 31 38-126
Fax: +49 (0)89-41 31 38-99
E-Mail: investors@wilex.com
This communication contains certain forward-looking statements relating to
the Company's business, which can be identified by the use of
forward-looking terminology such as 'estimates', 'believes', 'expects',
'may', 'will' 'should' 'future', 'potential' or similar expressions or by a
general discussion of the Company's strategy, plans or intentions. Such
forward-looking statements involve known and unknown risks, uncertainties
and other factors, which may cause our actual results of operations,
financial position, earnings, achievements, or industry results, to be
materially different from any future results, earnings or achievements
expressed or implied by such forward-looking statements. Given these
uncertainties, prospective investors and partners are cautioned not to
place undue reliance on such forward-looking statements. We disclaim any
obligation to update any such forward-looking statements to reflect future
events or developments.
15.07.2010 Ad hoc announcement, Financial News and Press Release distributed by DGAP.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: WILEX AG
Grillparzerstr. 10
81675 München
Deutschland
Phone: +49 (0)89 41 31 38 - 0
Fax: +49 (0)89 41 31 38 - 99
E-mail: info@wilex.com
Internet: www.wilex.com
ISIN: DE0006614720
WKN: 661472
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, Düsseldorf, München, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------------